ABCL · AbCellera Biologics
AI read · Good for ABCL
The AI's read
The trial result could help AbCellera move ABCL635 toward larger studies and a possible new treatment. Its $200 million raise and cash balance give it money to do that. The $41 million loss shows the company is still spending more than it brings in. It also reported over $10 million in quarterly sales and lower spending on sales and administration, at $14 million. The trial result and available cash support a favorable read despite the loss.